|
1
|
Malvezzi M, Bertuccio P, Levi F, et al:
European cancer mortality predictions for the year 2014. Ann Oncol.
25:1650–1656. 2014.PubMed/NCBI
|
|
2
|
Arrington AK, Heinrich EL, Lee W, et al:
Prognostic and predictive roles of KRAS mutation in colorectal
cancer. Int J Mol Sci. 13:12153–12168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Almoguera C, Shibata D, Forrester K, et
al: Most human carcinomas of the exocrine pancreas contain mutant
c-K-ras genes. Cell. 53:549–554. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kranenburg O: The KRAS oncogene: past,
present, and future. Biochim Biophys Acta. 1756:81–82.
2005.PubMed/NCBI
|
|
5
|
De Roock W, Piessevaux H, De Schutter J,
et al: KRAS wild-type state predicts survival and is associated to
early radiological response in metastatic colorectal cancer treated
with cetuximab. Ann Oncol. 19:508–515. 2008.PubMed/NCBI
|
|
6
|
Vogelstein B, Fearon ER, Hamilton SR, et
al: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bamford S, Dawson E, Forbes S, et al: The
COSMIC (Catalogue of Somatic Mutations in Cancer) database and
website. Br J Cancer. 91:355–358. 2004.PubMed/NCBI
|
|
8
|
Piessevaux H, Buyse M, Schlichting M, et
al: Use of early tumor shrinkage to predict long-term outcome in
metastatic colorectal cancer treated with cetuximab. J Clin Oncol.
31:3764–3775. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brink M, Weijenberg MP, de Goeij AF, et
al: Dietary folate intake and k-ras mutations in sporadic colon and
rectal cancer in The Netherlands Cohort Study. Int J Cancer.
114:824–830. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neumann J, Zeindl-Eberhart E, Kirchner T
and Jung A: Frequency and type of KRAS mutations in routine
diagnostic analysis of metastatic colorectal cancer. Pathol Res
Pract. 205:858–862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andreyev HJ, Norman AR, Cunningham D, et
al: Kirsten ras mutations in patients with colorectal cancer: the
‘RASCAL II’ study. Br J Cancer. 85:692–696. 2001.
|
|
12
|
Hamilton SR, Vogelstein B, Kudo S, et al:
Carcinom. of the colon and rectum. World Health Organization
classification of tumours. Pathology and genetics. Tumors of the
digestive system. IARC Press; Lyon: pp. 103–119. 2000
|
|
13
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brink M, de Goeij AF, Weijenberg MP, et
al: K-ras oncogene mutations in sporadic colorectal cancer in The
Netherlands Cohort Study. Carcinogenesis. 24:703–710. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zahrani A, Kandil M, Badar T, et al:
Clinico-pathological study of K-ras mutations in colorectal tumors
in Saudi Arabia. Tumori. 100:75–79. 2014.PubMed/NCBI
|
|
16
|
Gil Ferreira C, Aran V, Zalcberg-Renault
I, et al: KRAS mutations: variable incidences in a Brazilian cohort
of 8,234 metastatic colorectal cancer patients. BMC Gastroenterol.
14(73)2014.PubMed/NCBI
|
|
17
|
Bleeker WA, Hayes VM, Karrenbeld A, et al:
Impact of KRAS and TP53 mutations on survival in patients with
left- and right-sided Dukes' C colon cancer. Am J Gastroenterol.
95:2953–2957. 2000.PubMed/NCBI
|
|
18
|
Zulhabri O, Rahman J, Ismail S, et al:
Predominance of G to A codon 12 mutation K-ras gene in Dukes' B
colorectal cancer. Singapore Med J. 53:26–31. 2012.PubMed/NCBI
|
|
19
|
Minamoto T, Sawaguchi K, Mai M, et al:
Infrequent K-ras activation in superficial-type (flat) colorectal
adenomas and adenocarcinomas. Cancer Res. 54:2841–2844.
1994.PubMed/NCBI
|
|
20
|
Bazan V, Migliavacca M, Zanna I, et al:
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression,
predict outcome in colorectal cancer patients. Result of a 5-year
prospective study. J Cancer Res Clin Oncol. 128:650–658.
2002.PubMed/NCBI
|
|
21
|
Yamauchi M, Morikawa T, Kuchiba A, et al:
Assessment of colorectal cancer molecular features along bowel
subsites challenges the conception of distinct dichotomy of
proximal versus distal colorectum. Gut. 61:847–854. 2012.
View Article : Google Scholar
|
|
22
|
Guerrero S, Casanova I, Farre L, et al:
K-ras codon 12 mutation induces higher level of resistance to
apoptosis and predisposition to anchorage-independent growth than
codon 13 mutation or proto-oncogene overexpression. Cancer Res.
60:6750–6756. 2000.
|
|
23
|
De Roock W, Jonker DJ, Di Nicolantonio F,
et al: Association of KRAS p.G13D mutation with outcome in patients
with chemotherapy-refractory metastatic colorectal cancer treated
with cetuximab. Jama. 304:1812–1820. 2010.PubMed/NCBI
|
